| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 91 | — | 17.3x | Top tier | |
Growth | 52 | 4.9% | 7.1% | Around median | |
Quality | 30 | -31.6% | 4.5% | Bottom tier | |
Safety | 31 | 4.0x | 2.6x | Bottom tier | |
Capital Return | 50 | 0.00% | 0.06% | Around median | |
Momentum | 33 | -41.2% | -1.6% | Bottom tier | |
Sentiment | 92 | 7 | 3 | Top tier |
10-year US Treasury yield 4.96% as of 2026-10-22. Estimates computed from company data and analyst targets, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Enovis Corporation operates in orthopedic technology and musculoskeletal care through two main segments. The Recon segment sells joint reconstruction solutions, including hip, knee, shoulder, and extremity implants and instruments, with its growth supported by platforms such as ARG, Nebula, and the portable Arvis system; meanwhile, the Prevention & Recovery segment generates revenue from products including bracing, bone growth stimulation, cold therapy, and recovery solutions. In Q1 FY2026, organic growth was 6% in Recon and 1% in Prevention & Recovery, or 8% and 3%, respectively, after adjusting for the impact of selling days.
In Q2 FY2026, Enovis reported revenue of $582.8 million and gross profit of $359.2 million, equivalent to a gross margin of approximately 61.6%, while net loss was $1.2 million and loss per share was $0.02. This compares with revenue of $589.2 million, gross profit of $365.5 million, and a net loss of $8.8 million in Q1 FY2026, indicating a clear improvement in the bottom line despite the sequential decline in revenue.
On a trailing-twelve-month basis through Q2 FY2026, revenue was $2.3 billion and gross profit was $1.4 billion, but net loss reached $1.1 billion. FY2025 recorded revenue of $2.2 billion, gross profit of $1.3 billion, and a net loss of $1.2 billion, so converting operating growth into sustainable accounting profits remains a central factor in the stock analysis.
Automated analysis for informational purposes only — not investment advice.
The average analyst price target is $38.2, compared with a wide range of $27 to $51 and a consensus rating of “Buy”; the average is approximately 11.4% above the upper end of the 52-week range of $34.28. However, the net loss of $1.1 billion during the trailing twelve months through Q2 FY2026 makes the price-to-earnings ratio unavailable as a positive metric, so achieving the target valuation depends heavily on continued improvement in accounting profits and cash flow, not revenue growth alone.
Figures in the text are as of 2026-09-01; the live price is shown at the top of the page.
The company's organic growth was 3% in Q1 FY2026, or 6% after adjusting for the impact of fewer selling days, which represented a 240-basis-point headwind. Recon grew organically by 6%, and its U.S. business achieved growth of 8%, led by extremities at 10% and hip and knee at 6%. ARG contributed to double-digit shoulder growth, while Nebula continued to attract competing users to the hip portfolio.
Enovis began deploying Arvis during FY2026 after showcasing it at the AAOS conference in New Orleans in March 2026, initially focusing on shoulder surgeries and then knee surgeries. The system offers a flexible model that includes purchase, leasing, or payment per case with a volume commitment, and management views it as a way to convert competing surgeons and support the use of Enovis implants across multiple sites. However, Arvis did not generate material revenue in Q1 FY2026, so its importance depends on broader adoption during the remainder of FY2026.
Enovis reported a net loss of $1.2 million and a loss per share of $0.02 in Q2 FY2026, compared with a net loss of $8.8 million and a loss per share of $0.15 in Q1 FY2026. Gross margin in Q2 was approximately 61.6%, based on gross profit of $359.2 million and revenue of $582.8 million. Despite this sequential improvement, the trailing-twelve-month net loss remained at $1.1 billion.
Adjusted gross margin reached 62% in Q1 FY2026, up 40 basis points on an underlying basis, but the adjusted earnings before interest, taxes, depreciation, and amortization margin declined 10 basis points to 17.6%. The company absorbed approximately $4 million in tariffs, most of which was in Prevention & Recovery, along with shipping inflation and increased research and development investments. Conversely, free cash flow improved by $16 million year over year, and management reaffirmed a conversion target of more than 25% in FY2026.
Management said on May 7, 2026, that more than 25% of Enovis's primary knee procedures are performed in ambulatory surgery centers, while the shoulder share approached the teens and the hip share falls between them. Arvis's portability and use across multiple sites support the company's strategy in these centers, while the Recon and Prevention & Recovery portfolios enable it to serve broader stages of patient care. However, management also noted that the shift toward ambulatory surgery centers creates some pricing pressure in Recon, making volume and market-share gains necessary to offset it.